Hormonal Health Stigma Keeps 68% of Women From Seeking Help - Sex Hormones Awareness Week 2025 Calls for Change

As part of the initiative, the company released a comprehensive report on the State of Hormone Health 2025. 

SAN FRANCISCO, Feb. 17, 2025 /PRNewswire/ -- Mira, a leading hormonal health company, announces the second annual Sex Hormones Awareness Week. The event will take place from February 17 to 23, 2025. Building on last year's success, this initiative aims to spark meaningful conversations, advance research, and empower individuals with the knowledge needed to navigate their hormonal health.

This year marks 120 years since the discovery of hormones. Despite medical advancements, hormonal health remains under-researched and often misunderstood due to historical exclusion and stigma. In fact, Mira's report reveals that 68% of American women won't seek medical help for hormonal issues, even when experiencing severe symptoms like pain or hot flashes. The economic impact of untreated hormonal health is also substantial – 24% of women have left or considered leaving work due to their symptoms, which could result in an estimated $196 billion in lost productivity annually.

"Women have long been expected to endure pain, fatigue, and hormonal challenges as unavoidable parts of life. Our report reveals that 35% of women avoid activities like socializing or exercising due to hormonal symptoms. This year, we're not just raising awareness — we're highlighting real experiences and providing actionable insights to drive change," said Sylvia Kang, CEO and co-founder of Mira.

As part of this initiative, Mira is releasing the State of Hormonal Health 2025 report, which synthesizes years of data to identify key trends, gaps, and emerging insights in women's hormonal health. One of the shocking findings states that 4 in 10 women believe their symptoms aren't "serious enough" to seek medical attention, despite experiencing daily challenges like fatigue, pain, and irregular cycles. The report underscores how technological advancements, such as Mira's hormone-tracking tools, are empowering women with personalized data, enabling them to take charge of their health and make informed decisions.

"To address these issues, it's crucial to shift the narrative towards understanding and prioritizing hormonal health as a vital component of overall well-being. Femtech innovations like Mira are pivotal in democratizing access to hormonal health assessments, making it as fundamental and accessible as checking blood pressure. By simplifying and destigmatizing the process of hormonal testing and balancing, we empower women to take proactive steps toward health, fostering a culture where hormonal health is neither overlooked nor underestimated," Brittany Barreto, PhD Best Selling Author of Unlocking Women's Health.

Building on this momentum, Mira is also launching the first-ever Hormone Innovators Award, recognizing individuals, researchers, and organizations making groundbreaking contributions to hormonal health. This award celebrates those driving progress in research, treatment, and care across all stages of a woman's life. The call for applications will be announced in March.

This year, Sex Hormones Awareness Week is supported by partners such as ŌURA,, Hello Alpha, Tiny Health, FLO Living, and Femtech Insider bringing together leading experts in health technology, wellness, and hormonal health to support the mission of creating meaningful change.

For more details about Sex Hormones Awareness Week and to access resources, visit https://info.miracare.com/ .

About Mira

Mira is a San Francisco-based hormonal health company providing integrative care and hormonal testing for over 130,000 customers. Mira was founded in late 2015 by a group of scientists, engineers, OBGYN doctors, and business execs to solve the problem of the unavailability of advanced home health testing. The company's mission is to develop data-driven hormonal health solutions to help women make confident health decisions during every stage of their lives – from the menstrual stage to menopause.

For more information on Mira, please visit miracare.com. 

SOURCE Quanovate Tech Inc, dba Mira